First-episode psychosis: A clinical approach

Journal of the American Board of Family Practice

Volumn 13, Issue 6, 2000, Pages 430-439

  Schulz, S Charles ^a   Bass, Deanna ^b   Vrabel, Cynthia S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE;

ADULT; AGRANULOCYTOSIS; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG USE; EARLY DIAGNOSIS; FAMILY; FEMALE; GALACTORRHEA; GENERAL PRACTITIONER; HUMAN; HYPOTHERMIA; MANIC DEPRESSIVE PSYCHOSIS; MOTOR DYSFUNCTION; PATIENT CARE; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; TREATMENT OUTCOME;

EID: 0342467843     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/15572625-13-6-430     Document Type: Article

References (45)

1. Keith SJ, Regier DA, Judd LL. A national plan for schizophrenia research: report of the National Advisory Mental Health Council. Rockville, Md: Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Department of Health & Human Services. 1988.
2. Weinberger D, Berman KF, Zee RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986;43:114-24.
3. Liddle PF. Functional imaging - schizophrenia. Br Med Bull 1996;52:486-94.
4. Kendler KS, MacLean CJ, O'Neill FA, et al. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 1996;153: 1534-40.
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
6. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151: 825-35.
7. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
8. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
9. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.
10. Diagnostic and statistical manual of mental disorders (4th ed). Washington, DC: American Psychiatric Association, 1994.
11. Carlson GA, Fennig S, Bromet EJ. The confusion between bipolar disorder and schizophrenia in youth: where does it stand in the 1990s? J Am Acad Child Adolesc Psychiatry 1994:33:453-60.
12. McKenna K, Gordon CT, Lenane M, Kaysen D, Fahey K, Rapoport JL. Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994;33:636-44.
13. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States based on five epidemiologic catchment area sites. Arch Gen Psychiatry 1988;45:977-86.
14. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984;41:157-61.
15. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993;162: 80-6.
16. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry 1993;150:1349-54.
17. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
18. Fenton WS, Mosher LR, Herrell JM, Blyler CR. Randomized trial of general hospital and residential alternative care for patients with severe and persistent mental illness. Am J Psychiatry 1998;155:516-22.
19. Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year follow-up. Schizophr Bull 1993;19:831-41.
20. Kendler KS, MacLean CJ, Ma Y, O'Neill FA, Walsh D, Straub RE. Marker-to-marker linkage disequilibrium on chromosomes 5q, 6p, and 8p in Irish high-density schizophrenia pedigrees. Am J Med Genet 1999;88:29-33.
21. Straub RE, MacLean CJ, Martin RB, et al. A schizophrenia locus may be located in region 10p15-p11. Am J Med Genet 1998;81:296-301.
22. Wildenauer DB, Schwab SG. Chromosomes 8 and 10 workshop. Am J Med Genet 1999;88:239-43.
23. Blouin JL, Dombroski BA, Nath SK, et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998;20:70-3.
24. Chow EW, Mikulis DJ, Zipursky RB, Scutt LE, Weksberg R, Bassett AS. Qualitative MRI findings in adults with 22q11 deletion syndrome and schizophrenia. Biol Psychiatry 1999;46:1436-42.
25. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1979; 36:735-9.
26. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999;45: 1099-119.
27. Andreasen NC, Arndt S, Swayze V 2nd, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-8.
28. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
29. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135:165-73.
30. Schulz SC, Koller MM, Kishore PR, Hamer RM, Gehl JJ, Friedel RO. Ventricular enlargement in teenage patients with schizophrenia spectrum disorder. Am J Psychiatry 1983;140:1592-5.
31. Friedman L, Findling RL, Kenny JT, et al. An MRI study of adolescent patients with either schizophrenia or bipolar disorder as compared to healthy control subjects. Biol Psychiatry 1999;46:78-88.
32. Frazier JA, Giedd JN, Hamburger SD, et al. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Arch Gen Psychiatry 1996;53: 617-24.
33. DeLisi LE, Hoff AL, Schwartz JE, et al. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 1991;29:159-75.
34. Degreef G, Ashtari M, Bogerts B, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992;49:531-7.
35. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992;18:437-48.
36. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992;149:898-903.
37. Kenny JT, Friedman L, Findling RL, et al. Cognitive impairment in adolescents with schizophrenia. Am J Psychiatry 1997;154:1613-5.
38. Pool D, Bloom W, Mielke DH, Roninger JJ Jr, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976;19:99-104.
39. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984;141:440-2.
40. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369-76.
41. Simeon JG, Carrey NJ, Wiggins DM, Rowane WA, Friedman L, Schulz SC. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995;5:69-79.
42. Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6:251-7.
43. McConville B, Arvantis L, Wong J, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine in adolescents with selected psychotic disorders. Schizophrenia Res 1999;36:289.
44. Keegan DL, Albright P, Petersen T. Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia. Clin Drug Invest 1999; 18:233-7.
45. Davies MA. Parents of teenagers with psychosis. Presented at the Annual Meeting of the American Psychiatric Association, San Diego, May 1997:2.